October 2021 Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in Phase 1 Expansion Trial of BI 765063
October 2021 OSE Immunotherapeutics Presented Positive Final Results of Tedopi® Phase 3 Clinical Trial
October 2021 Boehringer Ingelheim and OSE Immunotherapeutics Present Phase 1 Results with First-in-Class SIRPα Inhibitor
October 2021 Boehringer Ingelheim and OSE Immunotherapeutics To Present Phase 1 Results with BI 765063